Candidate genes and polymorphism analysis in type 2 diabetes mellitus;Kandidatengene des diabetes mellitus typ 2: Gibt es einen gen-dosiseffekt für risikofaktoren sowie mikro- und makrovaskuläre folgeerkrankungen?

Medizinische Klinik

Volumn 101, Issue 8, 2006, Pages 605-616

  Zietz, Bettina ^a   Leonhardt, Katrin ^a   Schäffler, Andreas ^b  

^a Kreiskrankenhaus Kelheim ^*  (Germany)

^b Klinik und Poliklinik für Innere Medizin i Universitätsklinikum Halle Saale   (Germany)

Author keywords

Candidate gene; Diabetes mellitus type 2; Dyslipidemia; Polymorphism

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADIPONECTIN GENE; ADULT; AGED; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; DIABETIC MICROANGIOPATHY; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE SEVERITY; EXON; EYE PHOTOGRAPHY; FEMALE; GENE; GENE IDENTIFICATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SCREENING; GENOTYPE; GERMANY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PAI 1 GENE; PPARGAMMA2 GENE; QUESTIONNAIRE; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; UCP 1 GENE;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; BODY MASS INDEX; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DNA; DYSLIPIDEMIAS; EXONS; FEMALE; FUNDUS OCULI; GENOTYPE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; QUESTIONNAIRES; RISK FACTORS;

EID: 33747061256     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-006-1090-0     Document Type: Article

References (36)

1. Kellerer M, Hennige A, Häring HU. Typ 2 Diabetes - Pathogenese des Typ 2 Diabetes. In: Schatz H, Hrsg. Diabetologie Kompakt. Berlin-Wien: Blackwell Wissenschaft, 2001:107-14.
2. Nordt TK, Lohrmann J, Bode C. Regulation of PAI-1 expression by genetic polymoyrphisms impact on atherogenesis. Thromb Res 2001;103:Suppl:S1-5.
3. Barroso I, Luan J, Middelberg RPK, et al. Candidate gene association study in type 2 diabetes indicates a role for genes involved in beta-cell function as well as insulin action. PLoS Biol 2000;31:E20.
4. Malecki MT. Genetics of type 2 diabetes mellitus. Diabetes Res Clin Pract 2005;68:Suppl 1:S10-21.
5. So WY, Ng MCY, Lee SC, et al. Genetics of type 2 diabetes mellitus. Hong Kong Med J 2000;6:69-76.
6. Kadowaki T, Hara K, Yamauchi T, et al. Molecular mechanism of insulin resistance and obesity. Exp Biol Med 2003;228:1111-7.
7. Zietz B, Watzlawek E, Palitzsch KD, et al. GG-genotype in the promotor region of uncoupling-protein-1 gene is associated with lower level of DHEAS in diabetic patients. Exp Clin Endocrinol Diabetes 2001;109:102-6.
8. Zietz B, Barth N, Ottmann S, et al. Gly15Gly polymorphism within the human adipocyte-specific apM-1 gene but not Tyr111His polymorphism is associated with higher levels of LDL-cholesterol but lower incidence of retinopathy in caucasian subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2001;109:320-5.
9. Zietz B, Barth N, Spiegel D, et al. Pro 12Ala polymorphism in the gene of peroxisome proliferation-activated receptor-γ2 (PPARγ2) is associated with higher levels of total cholesterol and LDL-cholesterol in male caucasian type 2 diabetic patients. Exp Clin Endocrinol Diabetes 2002;110:60-6.
10. Zietz B, Drobnik W, Herfarth H, et al. Plasminogen activator inhibitor-1 promoter activity in adipocytes is not influenced by the 4G/5G promoter polymorphism and is regulated by an USF-1/-2 binding site immediately preceding the polymorphic region. J Mol Endocrinol 2004;32:155-63.
11. Zietz B, Herfarth H, Paul G, et al. Adiponectin represents an independent cardiovascular risk factor predicting serum HDL-cholesterol levels in type 2 diabetes. FEBS Lett 2002;545:103-4.
12. Zietz B, Büchler C, Drobnik W, et al. Allelic frequency of the PAI-1 4G/5G promoter polymorphism in patient with type 2 diabetes mellitus and lack of association with PAI-1 plasma levels. Endocr Res 2004;30:443-53.
13. Ferber L von, Salzsieder E, Hauner H, et al. Diabetes prevalence from health insurance data: evaluation of estimates by comparison with a population-based diabetes register. Diabete Metab 1993;19:89-95.
14. Michaelis D, Jutzi E, Vogt L. Epidemiology of insulin-treated diabetes mellitus in the East-German population. Diabete Metab 1993;19:110-5.
15. Kohner EM, Porta M. Protocols for screening and treatment of diabetic retinopathy in Europe. Eur J Ophthalmol 1991;1:45-54.
16. 1c- Analyse. Diabetes Stoffw 1999;8:189-200.
17. Ek J, Urhammer SA, Sorensen TI, et al. Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-gamma2 (PPAR-gamma2). Divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia 1999;42:892-5.
18. Schäffler A, Palitzsch KD, Watzlawek E. et al. Frequency and significance of the AG (-3826) polymorphism in the promoter gene of uncoupling protein-1 with regard to metabolic parameters and adipocyte transcription factor binding in a large population-based Caucasian cohort. Eur J Clin Invest 1999;29:770-9.
19. SPSS Inc. SPSS for Windows 95, V. 11.0. Chicago: SPSS, 2005.
20. Eriksson P, Kallin B, van't Hooft FM, et al. Allelic-specific increase in basal transcription of the plasminogen activator inhibitor-1 gene is associated with myocardial infarction. Thromb Haemost 1998;79:353-8.
21. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000;95:1517-32.
22. Panahloo A, Mohamed-Ali V, Lane A, et al. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator 1 gene. Diabetes 1995;44:37-42.
23. Gardemann A, Lohre J, Katz N, et al. The 4G/4G genotype of the plasminogen sctivator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. Thromb Haemost 1998;82:1121-6.
24. Anderson JL, Muhlestein JB, Habshi J, et al. Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary heart disease and myocardial infarction. J Am Coll Cardiol 1999;34:1778-83.
25. Iacoviello L, Burzotta F, Di Castelnuovo A, et al. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb Haemost 1998;80:1029-30.
26. Yen CJ, Beamer BA, Negri C, et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro 12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 1997;241:270-4.
27. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000;26:76-80.
28. Beamer BA, Yen CJ, Andersen RE, et al. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes 1998;47:1806-8.
29. Meirhaeghe A, Fajas L, Helbecque N, et al. Impact of the peroxisome proliferator activated receptor gamma2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int J Obes Relat Metab Disord 2000;24:155-9.
30. Oppert JM, Vohl CM, Chagnon M, et al. DNA polymorphism in the uncoupling protein (UCP) gene and human body fat. Int J Obes Relat Metab Disord 1994;18:526-31.
31. Urhammer SA, Fridberg M, Sorensen TIA, et al. Studies of gene variability of the uncoupling protein 1 gene in Caucasian subjects with juvenile-onset obesity. J Clin Endocrinol Metab 1997;82:4069-74.
32. Clément K, Ruiz J, Cassard-Doulcier AM, et al. Additive effect of A→G (-3826) variant of uncoupling protein gene and the Trp64Arg mutation of the β3-adrenergic receptor gene on weight gain in morbid obesity. Int J Obes Relat Metab Disord 1996;20:1062-6.
33. Fumeron F, Durack-Brown I, Cassard-Doulcier AM, et al. Polymorphisms of uncoupling protein (UCP) and β3 adrenoreceptor genes in obese people submitted to low caloric diet. Int J Obes Relat Metab Disord 1996;20:1051-4.
34. Amer P. Insulin resistance in type 2 diabetes - role of the adipokines. Curr Mol Med 2005;5:333-9.
35. Specter M. Decoding Iceland: the next big medical breakthroughs may result from one scientist's battle to map the Viking gene pool. New Yorker 1999;74:40, 42-6, 48-51.
36. Berger A. Private company wins rights to Icelandic gene database. BMJ 1999;318:11.